Sunday, 23 June 2024

Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix

29 March 2022 | News

Telix's lead product, Illuccix (kit for preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA), and by the Australian Therapeutic Goods Administration (TGA)

Image credit: shutterstock

Image credit: shutterstock

Australia-based Telix Pharmaceuticals has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuccix (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the United Kingdom (U.K.) and the Republic of Ireland.

Under the terms of the agreement, Xiel, a specialist distributor of Nuclear Medicine, Radiotherapy and Diagnostic Radiology technologies across the U.K. and Ireland will be the exclusive commercial distributor of Illuccix in the U.K. (a top 5 European market by GDP) and the Republic of Ireland for a period of three years from the national approval date.


Xiel replaces Curium as Telix's exclusive distribution partner in the U.K. and the Republic of Ireland.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account